Inhibitor Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Inhibitor Therapeutics has a total shareholder equity of $3.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $6.5M and $3.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$6.38m |
| Equity | US$3.41m |
| Total liabilities | US$3.04m |
| Total assets | US$6.45m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: INTI's short term assets ($6.5M) exceed its short term liabilities ($44.6K).
Long Term Liabilities: INTI's short term assets ($6.5M) exceed its long term liabilities ($3.0M).
Debt to Equity History and Analysis
Debt Level: INTI is debt free.
Reducing Debt: INTI had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: INTI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: INTI has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 34.5% each year.